Detection is the Key to Success
About Pearl Diagnostics
PearlDx is focused on development and commercialization of products to enable early detection and prevention of fungal infections.
Much progress in medicine is accompanied by risks for infections, caused by weakening of natural defenses in the immune system. People who receive organ transplantation, cancer therapy and medications to suppress the immune system have risks for infections caused by fungi. These organisms are everywhere in our environment and infections are difficult to treat. Prevention is a key step to improving outcomes. Our first product, a urine test to detect fungal infections in the lung, is in clinical studies now.
Pearl Diagnostics is located in the Johns Hopkins Fast Forward Accelerator in Baltimore, Maryland. This organization has been operating since 2014. PearlDx is a U.S. Small Business Administration-certified Women Owned Small Business (WOSB).
Company Announcements
October
Delivered oral presentation at the TIMM (Trends in Medical Mycology) meeting in Aberdeen, Scotland
View the Poster
View the Oral Presentation Slides
August
USPTO Issued United States Patent No. 11,079,380 on August 3, 2021 in PearlDx’s Name
View the Patent Notice
March
NIH Awards Phase II SBIR #AI157572-01 to PearlDx for further development of MycoMEIA – Urine Diagnostic for Aspergillosis on March 5, 2021
February
The PearlDx team presented 2 posters at the Transplantation & Cellular Therapy Meetings Feb. 8-12
Early Positive Results of the MycoMEIA™ Urine Assay Employed as a Screen to Diagnose Invasive Aspergillosis and Performance of the MycoMEIA™ Urine Assay As an Aid to Diagnose Invasive Aspergillosis
March
USPTO issued united States Patent No. 10,585,098 on March 10 in PearlDx’s Name
View the Patent Notice
July
Cystic Fibrosis Foundation awards grant to JHU and PearlDx: “Urine Diagnostics for Aspergillus Airway Disease”
May
USPTO issued United States Patent No. 10,288,611 on May 14, 2019 in PearlDx’s Name
View the Patent Notice
June
On June 23, 2019 at ASM Microbe in San Francisco the PearlDx team gave an oral presentation titled “URINE DIAGNOSTIC TESTS FOR ASPERGILLOSIS”.
Download the Poster
April
The PearlDx team gave an oral presentation on Characterisation of mAb476-reactive galactofuranose-bearing Aspergillus antigens excreted in urine, presented April, 2019 at 29th European Congress of Clinical Microbiology and Infectious Diseases 2019; Amsterdam, Netherlands
December
Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis published in Clinical Infectious Diseases, Volume 67, Issue 11, 1 December 2018, Pages 1705–1711
Click to Read the Article
April
The PearlDx team gave an oral presentation on Development and evaluation of a rapid urine diagnostic test for pulmonary aspergillosis, presented April 21, 2018 at 28th European Congress of Clinical Microbiology and Infectious Diseases 2018; Madrid Spain
February
Hopkins and PearlDx team presents poster on Urine Antigen Detection as an Aid to Diagnose Invasive Aspergillosis, presented Feb 3, 2018 at 8th Advances Against Aspergillus 2018; Lisbon Portugal
Download the Poster
July
Pearl Diagnostics announces receipt of NIH Phase II STTR to support clinical development of urine aspergillosis diagnostic test, MycoFlow-Asp™
June
Hopkins team and Pearl Diagnostics presents proof-of-concept data at the American Society of Microbiology (ASM) meeting in New Orleans, June 2-4
May
Pearl Diagnostics partners with the NIH-supported AsTeC repository to test urine diagnostic assay
Sponsors and Partners
